Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 230-525-2 | CAS number: 7173-51-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- GLP study, fully complying to OECD 417. No deviations. Criteria radiochemical purity and total radiation recovery were generally met. Recovery rates for dermal dose groups were slightly low. Some deviations from study plan occurred which are not considered to have compromised the validity or integrity of the study. Due to subsequent oral uptake of dermal applied dose, no information can be derived on quantitative dermal uptake from this study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 006
- Report date:
- 2005
Materials and methods
- Objective of study:
- toxicokinetics
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- Didecyldimethylammonium chloride
- EC Number:
- 230-525-2
- EC Name:
- Didecyldimethylammonium chloride
- Cas Number:
- 7173-51-5
- Molecular formula:
- C22H48N Cl
- IUPAC Name:
- didecyldimethylammonium chloride
- Details on test material:
- Unlabelled: Composition similar as
described in section 1.2 as typical marketed substance (act:40%, water 60%)
Composition: contains 40% Didecyldimethylammonium chloride (CAS no 7173-51-5) in 60% water. batchnumber; WIR03048
Labelled: [Methyl-14C]DDAC, purity: 98% in solution of IPA:water (2:3) batchnumber: CFQ13640
Constituent 1
- Radiolabelling:
- yes
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- -Source: Charles River Laboratories France, L’Arbresle, France. Caesarean Obtained, Barrier Sustained-Virus Antibody Free (COBS-VAF®).
-Sex: 60 males and 60 females.
-Age/weight at study initiation: Young adults approx. 7 weeks old; for the bile collection group, animals were around 10 weeks old.
-Number of animals per group: Kinetics (5 groups): 9 males & 9 females (3 /group/time/sex)
-Excretion balance: (3 groups): 5 males & 5 females
-Bile collection (1 group): 4 males & 4 females
-Control animals: Yes: For the purposes of pre-dose sample analysis, plasma, blood and tissues will be collected from at least one untreated supplementary animal/sex using the above mentioned procedures.
Administration / exposure
- Route of administration:
- other: Gavage and topical
- Vehicle:
- water
- Details on exposure:
- Refer to study design
- Duration and frequency of treatment / exposure:
- 6 hour(s)
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Males: oral 50 or 200; dermal 1.5 or 15 mg/kg bw/day
Females: oral 50 or 200; dermal 1.5 or 15 mg/kg bw/day
- No. of animals per sex per dose / concentration:
- Males: 64; Females: 64
- Control animals:
- no
- Positive control reference chemical:
- Not applicable
- Details on study design:
- The blood and plasma pharmacokinetics, tissue distribution and mass balance of total radioactivity of [14C] DDAC were evaluated following single dermal administration (at 1.5 and 15 mg/kg, as 6-hour exposure over 10% of the body surface) and single (at 50 and 200 mg/kg) and repeated (at 50 mg/kg/day) oral gavage administrations to male and female Sprague-Dawley rats. In addition, the elimination of radioactivity in bile after single oral administration at 50 mg/kg was investigated. Investigations included blood and plasma pharmacokinetics, tissue distribution and mass balance of total radioactivity.
The animals were divided into 9 groups; groups 1 to 5 (each of 9 animals/sex) for plasma/blood pharmacokinetics of radioactivity and tissue distribution, groups 6 to 8 (each of 5 animals/sex) principally for excretion balance and group 9 (4 animals/sex) for bile collection.
The animals wore an Elizabethan collar to prevent ingestion of the test item. At the end of the exposure period, the collar was removed and kept with the swabs for analysis. After 6 hours, the treated areas were washed using dampened cotton swabs with diluted hand soap followed by two dry swabs to remove all traces of the test item. - Details on dosing and sampling:
- Animals of groups 1 to 4 and 6 and 7 were treated once with the radiolabelled test item. Animals of groups 5 and 8 were treated once per day for 6 days with the unlabelled test item, followed by a single administration of the radiolabelled test item on the seventh day. All oral dosages applied 2.2 MBq/kg for radioactive dose-levels, and 3.7 MBq/kg for dermal applications. Dermal dosages were applied on clipped skin approx. 10% of the total body surface area, over the interscapular/upper back region.
Blood and plasma sampling:
Oral group: 0.5, 1, 2, 4, 8, 24, 48, 72 and 96 hours
Dermal group: 3 and 6 (i.e. during the exposure period), 7, 8, 10, 16, 24, 48 and 72 hours.
Following the final blood sampling/animal (i.e. at 24, 48 and 72/96 hours), each sampled animal was sacrificed by cervical dislocation, under isoflurane anesthesia. The carcass were weighed and the following tissues dissected out and weighed: Adrenals, Gastro intestinal tract (complete), Lymph nodes (mesenteric and mandibular), Brain, Heart, Muscle (right leg adductor), Eyes, Kidneys, Pancreas, Fat (abdominal), Liver, Skin (lower back), Femur (right with marrow), Lungs, Spleen. In addition, for the dermal treated animals, the application site will be dissected out and weighed. Thereafter, the application site and the skin from the lower back will be each stripped completely (using tape) 13 times. No macroscopic examination was performed on the prematurely sacrificed animals or those found dead.
Excreta: Urine and faeces were collected from the groups 6 to 8 animals for the radioactive treatments at the following times:
- during a period of 24 hours before radioactive dosing on day 1 (groups 6 and 7), or day 7 (group 8),
- and then during the periods 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours after the radioactive gavage/dermal application.
After each collection of faeces, the cages and trays were carefully rinsed with not more than 20 mL of water (cage wash) (except for last collection; approximately 100 mL were used). Expired CO2 was not collected as earlier studies with DDAC showed no radioactivity in the expired air. Any measurement of radioactivity lower then two times the blank was reported as BLQ (below the limit of quantification). - Statistics:
- Not reported
Results and discussion
Main ADME results
- Type:
- other: Absorption, distribution and excretion
- Results:
- Low dermal and oral absorption. The actual minimal fraction of the oral dose absorbed was 0.93 to 3.16%; this was eliminated rapidly, essentially within a 48 hour period.
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Oral:
Following single and/or repeated oral gavage at 50 and 200 mg/kg/day, the plasma and blood radioactivity levels were non-quantifiable indicating a low oral bioavailability. The actual minimal fraction of the oral dose absorbed was 0.93 to 3.16%; this was eliminated rapidly, essentially within a 48-hour period. The vast majority of the oral dose was excreted rapidly in the faeces.
Dermal:
Following single dermal application at 1.5 and 15 mg/kg, the plasma and blood radioactivity levels were non-quantifiable at all time-points. For the 1.5 mg/kg group, around 1% and 50% of the dose was eliminated in the urine and faeces, respectively, mostly within a 48-hour period, suggesting that the dermal dose was highly absorbed via the skin. However, as the test site was not protected with an Elizabethan collar during the main part of the collection period (the collar was worn during the exposure period only), this may have been due to the animal licking the test site. This is also supported with the finding that after oral dosing only 1-2.5% was excreted via bile back to intestines, and 2-3% excreted via urine. If similar routes of excretion are expected for dermal absorbed doses, it would not be possible to find levels of 50% of applied doses in intestines with only 1% excreted via urine. This indicates that about 50% of the dermal applied dose was taken up orally after all. - Details on distribution in tissues:
- Oral:
At the high oral dose-level only, quantifiable levels of radioactivity were found in some central organs at 24 hours post-dosing (intestines, liver., kidney) ; otherwise, the vast majority of the dose was confined to the intestines and levels decreased over time.
Dermal:
At 24 hours post-dosing, most of the radioactivity was in the "stripped" skin (dermis and epidermis) application site (6.07 to 21.6% of the dose) and intestines for both dose-levels, though some radioactivity was in the skin adjacent to the application site (most likely from cross-contamination due to grooming) and minor traces were in the eyes and other organs. At 72/168 hours, levels in the application site were 1.06 to 2.82% of the radioactive dose, suggesting the skin acted as a drug reservoir. In the stratum corneum of the application site, the levels of radioactivity were of similar magnitude in the different layers at each time point. For all tissues/organs, the radioactivity levels essentially decreased over time. All data showed generally a low inter-animal variability. In addition, there was no evidence of gender differences.
- Details on excretion:
- Oral:
Only 2.57/1.14% (males/females) of the oral dose was eliminated in the bile in a 24-hour period. No metabolites or parent drug were found in urine.
Dermal:
For the 1.5 mg/kg group, around 1% and 50% of the dose was eliminated in the urine and faeces, respectively, mostly within a 48-hour period.
Metabolite characterisation studies
- Metabolites identified:
- not measured
Any other information on results incl. tables
Conclusion:
Low dermal and oral absorption. The actual minimal fraction of the oral dose absorbed was 0.93 to 3.16%; this was eliminated rapidly, essentially within a 48 -hour period.
Applicant's summary and conclusion
- Conclusions:
- Low oral and probably negligible dermal absorption. The total oral absorption value was roughly in the range around 3-7%, based on urinary (0.93 - 3.16%) and bile (1.8-4.0%) excretion; elimination was rapidly, essentially within a 48 hour period.
- Executive summary:
The blood and plasma pharmacokinetics, tissue distribution and mass balance of total radioactivity of [14C] DDAC were evaluated following single dermal administration (at 1.5 and 15 mg/kg, as 6-hour exposure over 10% of the body surface) and single (at 50 and 200 mg/kg) and repeated (at 50 mg/kg/day) oral gavage administrations to male and female Sprague-Dawley rats. In addition, the elimination of radioactivity in bile after single oral administration at 50 mg/kg was investigated. Investigations included blood and plasma pharmacokinetics, tissue distribution and mass balance of total radioactivity.
Conclusion
Low oral and probably negligible dermal absorption. The total oral absorption value was roughly in the range around 3-7%, based on urinary (0.93 - 3.16%) and bile (1.8-4.0%) excretion; elimination was rapidly, essentially within a 48 hour period.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.